An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cybin, a biopharmaceutical company focused on mental health therapeutics, announced that CEO Doug Drysdale will present at the 2022 Virtual Growth Conference from March 28 to 30, 2022. The presentation will be available on demand starting March 28 at 9:00 a.m. ET. Interested attendees can register to access the conference and listen to the presentation via the company's website. Founded in 2019 and headquartered in Canada, Cybin is dedicated to advancing psychedelics for therapeutic use through innovative drug discovery and delivery systems.
Positive
None.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place March 28th - 30th from 9:00 a.m. - 5:00 p.m. ET.
Mr. Drysdale’s presentation will be available on demand beginning at 9:00 a.m. ET on Monday, March 28th. To attend, please register here to access the conference. To listen to the presentation, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
About Cybin Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.